NRX Pharmaceuticals, Inc. (NRXP) Form 8-K — Aug 17, 2026
NRx Pharmaceuticals reported Q2 2026 results with a six-month net loss of $18.0 million, improved from $23.1 million a year earlier, though net operating loss widened to $11.3 million from $7.6 million on launch-prep spending. Cash rose to $26.7 million from $7.8 million at year-end following a $22.3 million gross public offering, which management says funds operations for at least one year.
Key figures
- Net Income
- -$18.0 million for six months ended June 30, 2026 (vs -$23.1 million comparable 2025 period)
- Cash Position
- $26.7 million as of June 30, 2026 (vs $7.8 million as of December 31, 2025)
- Gross Proceeds
- $22.3 million from underwritten public offering including full exercise of underwriters' option
- Cash runway
- at least one year
- Addressable market
- 15 million+ Americans with treatment-resistant depression
- Launch stock doses
- 5000000
- Net operating loss
- $11.3 million for six months ended June 30, 2026 vs $7.6 million prior year
- Darpa nondilutive funding
- $11.5+ million (subject to completion of contracting)
- Real world evidence patients
- 65,000+
- Post launch monthly production
- 1000000
Price after filing
1 day: +0.3%7 days: +0.6%30 days: -2.3%
Close on the filing date to close N calendar days later (from $3.43). Historical, not a forecast.
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.